Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.
Their findings, reported in Nature Medicine, identify macrophages that express high levels of CD73, a surface enzyme that’s a vital piece of an immunosuppressive...
HOUSTON ― The University of Texas MD Anderson Cancer Center applauds the bipartisan legislation approved today raising the legal age...
Breast biopsies after neoadjuvant chemotherapy accurately predict presence of residual breast cancer
Abstract: GS5-04
Researchers from The University of Texas MD Anderson Cancer Center have identified a standardized protocol that uses...
Abstract: GS5-01
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes.
The study’s results were presented by W. Fraser Symmans, M.D., professor of Pathology, during the 2019...
The faculty and staff at The University of Texas MD Anderson Cancer Center congratulate Stephen Hahn, M.D., on his confirmation as United...
Abstract: GS1-01
Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition...
A study led by The University of Texas MD Anderson Cancer Center showed that treatment combining lower doses of chemotherapy with the monoclonal...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma...
A multi-institutional, Phase II study led by The University of Texas MD Anderson Cancer Center showed that pairing standard chemotherapy azacitidine...
The University of Texas MD Anderson Cancer Center convened an international panel of multidisciplinary experts earlier this year to evaluate...
After receiving acupuncture treatment three days a week during the course of radiation treatment, head and neck cancer patients experienced...
J. Jack Lee, Ph.D., associate vice president of Quantitative Sciences and Biostatistics at The University of Texas MD Anderson Cancer Center...
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can...
The University of Texas MD Anderson Cancer Center will honor business entrepreneur and philanthropist Jim Crane, owner and chairman of the...
Newly diagnosed prostate cancer patients have multiple standard-of-care treatment options available, but many are not fully informed of their...
The University of Texas MD Anderson Cancer Center marks the 10th year of A Conversation With a Living Legend® in San Antonio with a luncheon...
Prostate cancer that spreads to the bone triggers the destruction of bone tissue that, in turn, thwarts the effectiveness of immune checkpoint...
Researchers from The University of Texas MD Anderson Cancer Center reported that secondary tumor-reduction, or cytoreduction, surgery followed...
Kim Carstens, B.S.N., R.N., O.C.N., is the recipient of the 2019 Brown Foundation Award for Excellence in Oncology Nursing at The University...
The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios...
The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited today announced an exclusive license agreement...
For nearly 80 years, The University of Texas MD Anderson Cancer Center has been a global leader in the fight to end cancer. Our patients trust...
On Saturday, Nov. 9, The University of Texas MD Anderson Cancer Center will welcome thousands of cancer survivors and supporters to the Texas...
The University of Texas MD Anderson Cancer Center has named Allyson Hancock Kinzel, J.D., as senior vice president and chief legal officer...
The University of Texas MD Anderson Cancer Center and the University of Puerto Rico received a competitive renewal of their Comprehensive...
Ziopharm Oncology, Inc., and The University of Texas MD Anderson Cancer Center today announced a new research and development agreement relating...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed volunteer advisory board, welcomes seven...
The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software...
The North Texas A Conversation With a Living Legend® will honor Los Angeles Dodgers starting pitcher Clayton Kershaw in an interview with...
The University of Texas MD Anderson Cancer Center today opened its newest free-standing facility in The Woodlands. Serving patients in The...
Abstract: LBA32
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in...
Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in...
Abstract: LBA3
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment...
In the largest smoking cessation study of cancer patients to date, researchers from The University of Texas MD Anderson Cancer Center...
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment...
The University of Texas MD Anderson Cancer Center has awarded Sheryl Harris, C.N.A., the Julie and Ben Rogers Award for Excellence in Patient...
The University of Texas MD Anderson Cancer Center goes gold for Kick Childhood Cancer Awareness Night at BBVA Stadium, Saturday, Sept. 21...
The University of Texas MD Anderson Cancer Center extends deepest sympathy to family and friends of philanthropist and energy...
Researchers at The University of Texas MD Anderson Cancer Center have confirmed a protein as an oncogene responsible for the most common and...
The University of Texas MD Anderson Cancer Center supports efforts by the Food and Drug Administration and the Centers for Disease Control...
The University of Texas MD Anderson Cancer Center received a notice of renewal from the National Cancer Institute (NCI) to extend its status...
The University of Texas MD Anderson Cancer Center today was awarded more than $19 million from the Cancer Prevention and Research Institute...
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, will attend the TOUR Championship for the fifth...
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative...
A key difference between the few pancreatic cancer patients who survive long-term and the many whose disease overcomes...
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a groundbreaking ceremony. The...
The University of Texas MD Anderson Cancer Center is honored to be ranked No. 1 in cancer care in the U.S. News & World Report’s annual...
Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative...
A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing...
The tobacco industry’s court-ordered anti-smoking advertisements reached just 40.6% of U.S. adults and 50.5% of current smokers in 2018, according...
The University of Texas MD Anderson Cancer Center, the official cancer center of the PGA TOUR, today announced its partnership with Joel Dahmen...
More than 140,000 people from around the world turned to our experts last year for their cancer care. Their trust in MD Anderson pushes us...
The University of Texas MD Anderson Cancer Center today named Darrow Zeidenstein, Ph.D., as chief development officer. With more than 25 years...
The University of Texas MD Anderson Cancer Center has cooperated fully in two surveys conducted by the Centers for Medicare and Medicaid Services...
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages...
ABSTRACT #7508
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination...
ABSTRACT 8504
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response...
ABSTRACT LBA1008
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal...
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given...
The University of Texas MD Anderson Cancer Center applauds the Texas Legislature today for passing Senate Bill 21, which raises the minimum...
The University of Texas MD Anderson Cancer Center today named David Jaffray, Ph.D., as its first-ever chief technology and digital officer...
Despite a Saturday morning storm that wreaked havoc on plans for this year’s Polo on the Prairie, May 18 at the Musselman Brothers’ Lazy 3...
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder...
The University of Texas MD Anderson Cancer Center applauds the 86th Texas Legislature today for voting to approve a constitutional amendment...
The University of Texas MD Anderson Cancer Center has received full accreditation by the American Association for Physician Leadership...
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered...
The University of Texas MD Anderson Cancer Center has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each...
A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer...
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment...
HOUSTON – The University of Texas MD Anderson Children’s Cancer Hospital joins Peli Peli Restaurants, the National Association for Catering...
The impact of foreign influence across multiple sectors of the United States economy continues to be a national concern. Specific to academia...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop...
The University of Texas MD Anderson Cancer Center proudly presents End Cancer Night at BBVA Compass Stadium Saturday, April 27 at 7 p.m. as...
A study at The University of Texas MD Anderson Cancer Center revealed the investigational drug umbralisib as an effective treatment for patients...
Cancer cells demand enormous amounts of molecular “food” to survive and grow, and a study published March 27 online in Nature by researchers...
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint...
Researchers at The University of Texas MD Anderson Cancer Center revealed the common oncogene KRAS as a possible explanation for why many...
The University of Texas MD Anderson Cancer Center presents its Making Cancer History® Seminar, 11:30 a.m.-1:30 p.m. March 25 at the Hotel...
Lung cancer is the leading cancer killer, yet coverage of screenings for individuals at high risk for lung cancer varies across state Medicaid...
A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center returns to Palm Beach with its Making Cancer History® Seminar, 9-11 a.m. March 18 at The...
The University of Texas MD Anderson Cancer Center has named Giulio Draetta, M.D., Ph. D. as chief scientific officer (CSO), a new position...
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test...
The University of Texas MD Anderson Cancer Center today was awarded $19.6 million from the Cancer Prevention and Research Institute of Texas...
Melanoma tumors that have spread to the brain are equipped to thwart immunotherapies and targeted therapies that succeed against tumors growing...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted...
Some patients with metastatic prostate cancer respond to a combination of immune checkpoint inhibitors after hormonal therapy and chemotherapy...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that malignant rhabdoid tumors (MRT), a rare pediatric cancer...
As an institution devoted to eliminating cancer for patients in Texas, the nation and around the world, The University of Texas MD Anderson...
Researchers at The University of Texas MD Anderson Cancer Center have discovered an immune regulator that appears to dictate glioblastoma...
The University of Texas MD Anderson Cancer Center today named Rosanna Morris, RN, MBA, as chief operating officer (COO). With more than 20...
The University of Texas MD Anderson Cancer Center and Dragonfly Therapeutics, Inc., today announced a strategic collaboration to bring Dragonfly...
Complication rates and costs of invasive lung cancer diagnostic tests may be higher than anticipated
Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to...
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment...
By analyzing variations in the level of human papillomavirus (HPV) in head and neck cancers, researchers at The University of Texas MD Anderson...
John Mendelsohn, M.D., president emeritus of The University of Texas MD Anderson Cancer Center and an internationally acclaimed leader in...
The University of Texas MD Anderson Cancer Center and Nanobiotix today announced a large-scale, comprehensive clinical research collaboration...
The University of Texas MD Anderson Cancer Center and Ascentage Pharma Group, Inc. today announced a five-year strategic collaboration agreement...
MD Anderson Cancer Center and 4D pharma collaborate to evaluate live biotherapeutics in solid tumors
The University of Texas MD Anderson Cancer Center and 4D pharma today announced a strategic collaboration to evaluate 4D’s live biotherapeutic...
Waun Ki Hong, M.D., a trail-blazing physician-scientist and mentor whose clinical research innovations led to successful organ-sparing cancer...